Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Zai Lab Ltd ( (HK:9688) ).
Zai Lab Limited has announced that its Audit Committee will review and approve the unaudited interim results for the first half of 2025 on August 7, 2025. The results, prepared in accordance with U.S. GAAP and SEC rules, will be published on the same day. Following the announcement, the company will host a live earnings teleconference and webcast to discuss the results. This announcement signifies Zai Lab’s commitment to transparency and adherence to regulatory standards, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative therapies. The company operates in the healthcare industry, with a market focus on addressing significant unmet medical needs.
Average Trading Volume: 13,846,098
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.15B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.